Logo image of PTIX

PROTAGENIC THERAPEUTICS INC (PTIX) Stock Fundamental Analysis

USA - NASDAQ:PTIX - US74365N3017 - Common Stock

2.03 USD
-0.07 (-3.33%)
Last: 11/14/2025, 8:18:25 PM
2.07 USD
+0.04 (+1.97%)
After Hours: 11/14/2025, 8:18:25 PM
Fundamental Rating

1

Taking everything into account, PTIX scores 1 out of 10 in our fundamental rating. PTIX was compared to 531 industry peers in the Biotechnology industry. PTIX has a bad profitability rating. Also its financial health evaluation is rather negative. PTIX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year PTIX has reported negative net income.
PTIX had a positive operating cash flow in the past year.
PTIX had negative earnings in each of the past 5 years.
In the past 5 years PTIX always reported negative operating cash flow.
PTIX Yearly Net Income VS EBIT VS OCF VS FCFPTIX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -1M -2M -3M -4M -5M

1.2 Ratios

PTIX's Return On Assets of -133.97% is on the low side compared to the rest of the industry. PTIX is outperformed by 83.43% of its industry peers.
Industry RankSector Rank
ROA -133.97%
ROE N/A
ROIC N/A
ROA(3y)-147.64%
ROA(5y)-153.54%
ROE(3y)-244.56%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PTIX Yearly ROA, ROE, ROICPTIX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500 -500 1K -1K -1.5K

1.3 Margins

PTIX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PTIX Yearly Profit, Operating, Gross MarginsPTIX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025

More info and screens

2

2. Health

2.1 Basic Checks

The number of shares outstanding for PTIX has been increased compared to 1 year ago.
PTIX has more shares outstanding than it did 5 years ago.
PTIX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
PTIX Yearly Shares OutstandingPTIX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100K 200K 300K 400K 500K
PTIX Yearly Total Debt VS Total AssetsPTIX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M 10M

2.2 Solvency

PTIX has an Altman-Z score of -6.26. This is a bad value and indicates that PTIX is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -6.26, PTIX is not doing good in the industry: 64.78% of the companies in the same industry are doing better.
PTIX has a debt to FCF ratio of 4.11. This is a neutral value as PTIX would need 4.11 years to pay back of all of its debts.
The Debt to FCF ratio of PTIX (4.11) is better than 92.47% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 4.11
Altman-Z -6.26
ROIC/WACCN/A
WACCN/A
PTIX Yearly LT Debt VS Equity VS FCFPTIX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5M

2.3 Liquidity

PTIX has a Current Ratio of 0.41. This is a bad value and indicates that PTIX is not financially healthy enough and could expect problems in meeting its short term obligations.
The Current ratio of PTIX (0.41) is worse than 93.41% of its industry peers.
A Quick Ratio of 0.41 indicates that PTIX may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.41, PTIX is doing worse than 93.03% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.41
Quick Ratio 0.41
PTIX Yearly Current Assets VS Current LiabilitesPTIX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M 10M

More info and screens

0

3. Growth

3.1 Past

PTIX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 52.76%, which is quite impressive.
EPS 1Y (TTM)52.76%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%72.99%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PTIX Yearly EPS VS EstimatesPTIX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 -5 -10 -15 -20

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PTIX. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PTIX Price Earnings VS Forward Price EarningsPTIX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Compared to the rest of the industry, the Price/Free Cash Flow ratio of PTIX indicates a rather cheap valuation: PTIX is cheaper than 99.81% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 3.97
EV/EBITDA N/A
PTIX Per share dataPTIX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6 -8

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PTIX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PROTAGENIC THERAPEUTICS INC

NASDAQ:PTIX (11/14/2025, 8:18:25 PM)

After market: 2.07 +0.04 (+1.97%)

2.03

-0.07 (-3.33%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2025-11-12
Earnings (Next)03-30 2026-03-30
Inst Owners5.22%
Inst Owner Change0%
Ins Owners4.35%
Ins Owner Change0%
Market Cap3.88M
Revenue(TTM)N/A
Net Income(TTM)-8.69M
Analysts82.86
Price TargetN/A
Short Float %0.08%
Short Ratio0
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF 3.97
P/OCF 3.97
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-9.61
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0.51
FCFY25.17%
OCF(TTM)0.51
OCFY25.17%
SpS0
BVpS-2.08
TBVpS-3.18
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -133.97%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-147.64%
ROA(5y)-153.54%
ROE(3y)-244.56%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 4.11
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.41
Quick Ratio 0.41
Altman-Z -6.26
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)52.76%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%72.99%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-0.63%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y198.57%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y198.57%
OCF growth 3YN/A
OCF growth 5YN/A

PROTAGENIC THERAPEUTICS INC / PTIX FAQ

What is the ChartMill fundamental rating of PROTAGENIC THERAPEUTICS INC (PTIX) stock?

ChartMill assigns a fundamental rating of 1 / 10 to PTIX.


What is the valuation status for PTIX stock?

ChartMill assigns a valuation rating of 2 / 10 to PROTAGENIC THERAPEUTICS INC (PTIX). This can be considered as Overvalued.


What is the profitability of PTIX stock?

PROTAGENIC THERAPEUTICS INC (PTIX) has a profitability rating of 0 / 10.


What is the financial health of PROTAGENIC THERAPEUTICS INC (PTIX) stock?

The financial health rating of PROTAGENIC THERAPEUTICS INC (PTIX) is 2 / 10.